

**Appendix Table A1:** Findings Associated with Reported Cases of Linezolid Optic Neuropathy.

Study author(s)	Duration of linezolid use to first ocular symptoms (days)	Duration of linezolid use until cessation (days)	Linezolid dose	Cumulative dose of linezolid (g)	Visual acuity when diagnosed	Visual acuity at recovery	Time to maximum recovery
Javaheri, et al. <sup>2</sup>	365	365	170mg BID	124.1	20/400 OU	20/20 OU	2 weeks to 20/25 OU, 3 months to 20/20 OU
Lee et al. <sup>9</sup> (#1)	280	280	Not reported	Not reported	20/200 OU	20/30 OD, 20/25 OS	9 months
Lee, et al. <sup>9</sup> (#2)	308	308	Not reported	Not reported	20/80 OU	20/30 OD, 20/40 OS	6 months
McKinley and Foroozan <sup>10</sup> (#1)	180	448	600mg daily	108	20/400 OD, CF at 4° OS	20/25 OD, 20/30 OS	4 months
McKinley and Foroozan <sup>10</sup> (#2)	240	330	600mg daily	72	20/100 OU	20/40 OD, 20/25 OS	3 months
Rucker, et al. <sup>11</sup> (#1)	300	300	600mg BID	360	CF OD, 20/400 OS	CF OD (amblyopia), 20/30 OS	6 months
Rucker, et al. <sup>11</sup> (#2)	180	180	600mg BID	216	20/200 OD	20/40 OD	4 months
Rucker, et al. <sup>11</sup> (#3)	150	150	600mg BID	180	20/70 OD	20/25 OD	Not reported
Libersteyn <sup>12</sup>	3 months prior to cessation	"several months"	600mg BID	unknown	20/400 OD, CF at 5° OS	20/30 OD, 20/40 OS	3 months
Saijo, et al. <sup>13</sup>	154	194	Not reported	Not reported	20/200 OD, 20/400 OS	20/20 OU	Not reported
Kulkarni and Del Priore <sup>14</sup>	1125	1335	600mg BID x 12 mos, then 600mg daily x 44 mos	894	20/400 OU	20/40 OU	Not reported
Chaitali and Suresh <sup>15</sup>	240	270	600mg qd	144	CF 3m OD, 20/80 OS	20/80 OD, 20/30 OS	3 months
Karuppannasamy, et al. <sup>16</sup>	180	210	600mg qd	108	20/200 OU	20/20 OU	1 month
Han, et al. <sup>17</sup>	600	600	Not reported	Not reported	20/30 OD, 20/40 OS	20/20 OU	2 months
Joshi, et al. <sup>18</sup>	16	16	Not reported	Not reported	20/120 OD, 20/20 OS	20/20 OU	6 weeks
Azamfirei, et al. <sup>19</sup>	16	16	600mg BID	19.2	20/120 OU at near	"complete blindness"	17 months to latest reported examination
Park DH, et al. <sup>20</sup>	180	180	not reported	Not reported	20/50 OD, 20/100 OS	20/20 OD, 20/25 OS	4 months
Agrawal, et al. <sup>21</sup>	28	28	600mg qd	16.8	20/80 OD, 20/25 OS	20/20 OU	1 month
Schecter, et al. <sup>22</sup>	300	Not reported	Not reported	Not reported	Not reported	"return to normal"	3-4 weeks
Kiuchi, et al. <sup>23</sup>	730	767	"600-1200mg/day"	Unknown	20/333 OD, 20/250 OS	20/25 OD, 20/25+ OS	144 days
Park IN, et al. <sup>24</sup> (#1)	240	Not reported	600mg BID x 2 weeks, then 600mg daily for duration	151.2	Not reported	"optic neuropathy fully resolved"	Not reported
Park IN, et al. <sup>24</sup> (#2)	270	Not reported	600mg BID x 2 weeks, then 600mg daily for duration	169.2	Not reported	"optic neuropathy fully resolved"	Not reported
Mehta, et al. <sup>7</sup> (#1)	210	210	600mg daily	126	20/200 OD/OS	20/20 OD/OS	22 days
Mehta, et al. <sup>7</sup> (#2)	300	300	600mg daily	180	20/80 OD/OS	20/20 OD/OS	45 days
Mehta, et al. <sup>7</sup> (#3)	330	330	600mg daily	198	20/200 OD/OS	20/20 OD/OS	45 days
Mehta, et al. <sup>7</sup> (#4)	330	330	600mg daily	198	20/150 OD, 20/100 OS	20/20 OD/OS	78 days

Mehta, et al. <sup>7</sup> (#5)	330	330	600mg daily	198	20/200 OD/OS	Not reported	Not reported
Ishii, et al. <sup>25</sup>	203	210	Not reported	Not reported	0.06 OD, 0.07 OS	20/15 OD/OS	42 days
Frippiat, et al. <sup>26</sup>	287	308	Not reported	Not reported	Not reported	Not reported	Not reported
Lewis, et al. <sup>27</sup>	120	120	600mg BID	144	Counting fingers OD/OS	Not reported	Not reported
Corallo and Paull <sup>28</sup>	180	180	600mg BID	216	Not reported	Not reported	Five months
Khadilkar, et al. <sup>29</sup> (#1)	10	30	300mg BID	18	20/40 OD, 20/30 OS	"completely improved"	2 months
Khadilkar, et al. <sup>29</sup> (#2)	210	270	300mg BID	162	20/120 OD, CF 4' OS	No improvement	No improvement
Khadilkar, et al. <sup>29</sup> (#3)	180	210	300mg BID	126	20/40 OD/OS	"completely improved"	15 days
Hernández, et al. <sup>30</sup>	150	150	600mg BID	180	Not reported	Not reported	15 days
Xerri, et al. <sup>31</sup>	210	270	600mg daily	162	Counting fingers OD/OS	20/50 OD, 20/400 OS	5 months
Eisenack, et al. <sup>32</sup>	90	90	Not reported	Not reported	20/400 OD, counting fingers OS	20/15 OD, 20/20 OS	2 months
Rosenzweig et al. <sup>33</sup>	240	240	Not reported	Not reported	Not reported	"significant, but not complete recovery"	Not reported
Dempsey et al.	344	365	600mg BID	412.8	20/80 OD, 20/150 OS	20/20 OD, 20/40 OS	25 days

## **APPENDIX REFERENCES**

1. De Vries A, Coster R, Smet J, et al. Linezolid-Induced Inhibition of Mitochondrial Protein Synthesis. *Clin Infect Dis* 2006;42:1111-7.
2. Javaheri M, Khurana R, O'hearn T M, et al. Linezolid Induced Optic Neuropathy: A Mitochondrial Disorder? *The Br J Ophthalmol* 2007;91:111-5.
3. Wang MY, Sadun AA. Drug-Related Mitochondrial Optic Neuropathies. *J NeuroOphthalmol* 2013;33:172-8.
4. Li J, Tripathi R, Tripathi B. Drug-Induced Ocular Disorders. *Drug Saf* 2008;31:127-41.
5. Zhang X, Falagas ME, Vardakas KZ, et al. Systematic Review and Meta-analysis of the Efficacy and Safety of Therapy with Linezolid Containing Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. *J Thorac Dis* 2015;7:603-15.
6. Sotgiu G, Centis R, D'Ambrosio L, et el. Efficacy, Safety and Tolerability of Linezolid Containing Regimens in Treating MDR-TB and XDR-TB: Systematic Review and Meta-analysis. *Eur Respir J* 2012; 40:1430-42.
7. Mehta S, Das M, Laxmeshwar C, et al. Linezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, India. *PLoS One* 2016;11:e0162138.
8. Dryden MS. Linezolid Pharmacokinetics and Pharmacodynamics in Clinical Treatment. *J Antimicrob Chemother* 2011;66(Suppl. 4):iv7-iv15.
9. Lee E, Burger S, Press R, et al. Linezolid-Associated Toxic Optic Neuropathy: A Report of 2 Cases. *Clin Infect Dis* 2003;37:1389-91.
10. McKinley S, Foroozan R. Optic Neuropathy Associated with Linezolid Treatment. *J Neuroophthalmol* 2005;25:18-21.

11. Rucker J, Hamilton S, Bardenstein D, et al. Linezolid Associated Toxic Optic Neuropathy. Neurology 2006;66:595-8.
12. Libershteyn Y. Ethambutol/Linezolid Toxic Optic Neuropathy. Optom Vis Sci 2016;93:211-7.
13. Saijo T<sup>1</sup>, Hayashi K, Yamada H, Wakakura M. Linezolid-Induced Optic Neuropathy. Am J Ophthalmol 2005;139:1114-6.
14. Kulkarni K, Del Priore LV. Linezolid Induced Toxic Optic Neuropathy. Br J Ophthalmol 2005;89:1664-5.
15. Chaitali P, Suresh R. Comment on Linezolid Induced Optic Neuropathy. Indian J Ophthalmol 2015;63:75-6.
16. Karuppannasamy D, Raghuram A, Sundar D. Linezolid-Induced Optic Neuropathy. Indian J Ophthalmol 2014;62:497-500.
17. Han J, Lee K, Rhiu S, et al. Linezolid-Associated Optic Neuropathy in a Patient with Drug-Resistant Tuberculosis. J Neuroophthalmol 2013;33:316-8.
18. Joshi L, Taylor S, Large O, et al. A Case of Optic Neuropathy after Short-Term Linezolid Use in a Patient with Acute Lymphocytic Leukemia. Clin Infect Dis 2009;48:e73-4.
19. Azamfirei L, Copotoiu S, Branzaniuc K, et al. Complete Blindness after Optic Neuropathy Induced by Short-Term Linezolid Treatment in a Patient Suffering from Muscle Dystrophy. Pharmacoepidemiol Drug Saf 2007;16:402-4.
20. Park D, Park T, Ohn Y, et al. Linezolid Induced Retinopathy. Doc Ophthalmol 2015;131:237-44.

21. Agrawal R, Addison P, Saihan Z, et al. Optic Neuropathy Secondary to Linezolid for Multidrug-Resistant Mycobacterial Spinal Tuberculosis. *Ocul Immunol Inflamm* 2015;23:90-2.
22. Schechter G, Scott C, True L, et al. Linezolid in the Treatment of Multidrug-Resistant Tuberculosis. *Clin Infect Dis* 2010;50:49-55.
23. Kiuchi K, Miyashiro M, Kitagawa C, Wada S. Linezolid-Associated Optic Neuropathy in a Patient with Ocular Sarcoidosis. *Jpn J Ophthalmol* 2009;53:420-4
24. Park I, Hong S, Shim T, et al. Efficacy and Tolerability of Daily-Half Dose Linezolid in Patients with Intractable Multidrug-Resistant Tuberculosis. *J Antimicrob Chemother* 2006;58:701-4.
25. Ishii N, Kinouchi R, Inoue M, Yoshida A. Linezolid-Induced Optic Neuropathy with a Rare Pathological Change in the Inner Retina. *Int Ophthalmol* 2016;36:761-6.
26. Frippiat, F., Bergiers, C., Michel, C., et al. Severe Bilateral Optic Neuritis Associated with Prolonged Linezolid Therapy. *J Antimicrob Chemother* 2004;53:1114-5.
27. Lewis K, Ebden P, Wooster S, et al. Multi-System Infection with *Nocardia farcinica*-Therapy with Linezolid and Minocycline. *J Infect* 2003;46:199-202.
28. Corallo C, Paull A. Linezolid-Induced Neuropathy. *Med J Aust* 2002;177:332.
29. Khadilkar S, Yadav R, Rajan S. Linezolid Optic Neuropathy: Be Careful and Quick. *J Assoc Physicians India* 2013;61:866-7.
30. Hernández Prats C, Llinares Tello F, Climent Grana E, Fernández Aracil C. [Peripheral and Optic Neuropathy Associated to Linezolid in Multidrug Resistant *Mycobacterium bovis* Infection]. *Med Clin (Barc)* 2005;124:797-8.

31. Xerri O, Lemaire B, Nasser G, et al. [Severe Linezolid-Induced Toxic Optic Neuropathy]. J Fr Ophthalmol 2015;38:e55-8.
32. Eisenack J, Landau K, Wildberger H, Knecht P. [Linezolid-Associated Optic Neuropathy?]. Klin Monbl Augenheilkd 2012;229:433-4.
33. Rosenzweig S, Yancoski J, Calle G, et al. Thirteen Years of Culture-positive *M. bovis*-BCG Infection in an IL-12R $\beta$ 1 Deficient Patient: Treatment and Outcome. J Infect 2006;52(3):e69-72.